Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630201 · ClinicalTrials.gov registry record · Phase 3
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT00630201 is a Phase 3 study that has completed, run by Titan Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT00630201, a Phase 3 study, has completed, sponsored by Titan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patient with opioid dependence. Patients who have completed 24 weeks of treatment in the Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence, will be re-treated with Probuphine over an additional 24 weeks.
Interventions
- DRUG Probuphine (buprenorphine implant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630201
The ClinicalTrials.gov registry entry for NCT00630201 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Probuphine (buprenorphine implant) is the first listed.
NCT00630201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630201 about?
NCT00630201 is a clinical study titled "Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence". Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is d...
What is the current status of trial NCT00630201?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2007-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00630201?
The interventions under investigation include: Probuphine (buprenorphine implant) (DRUG).
Who is sponsoring clinical trial NCT00630201?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.